Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
EIKN
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
finance.yahoo.comPOSITIVO
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
Eikon Therapeutics, Inc. MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address seriou…
Eupraxia Pharmaceuticals Appoints New Technical Operations Heads; Co-Founder Malone Steps Down
(RTTNews) - Eupraxia Pharmaceuticals Inc. (EPRX), a clinical-stage biotechnology company, announced several leadership changes within the company to support its upcoming planned phase of clinical and commercial growth. The company appointe…
Is Eikon Therapeutics, Inc. (EIKN) Stock a Biotech Growth Opportunity Despite Limited Q1 Updates?
We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. Eikon Therapeutics, Inc. (NASDAQ:EIKN) is one of the best up and coming stocks on our list. TheFly reported on June 3 that BofA Securities lowered it…
Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology
TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continu…
Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates
Closed upsized initial public offering in February 2026, raising $381 million in gross proceedsCompleted enrollment of the TeLuRide-005 Phase 2 trial of EIK1001 in first-line treatment of stage 4 non-small cell lung cancer MILLBRAE, Calif.…
Catalyst Watch: Jobs report, new Apple products, and a spotlight on software
[New York Stock Exchange] Selcuk Oner/iStock Editorial via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock price…
Spotify upgraded, First Solar downgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: Arete upgraded Spotify (SPOT) to Buy from Ne…
Spotify upgraded, First Solar downgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: Arete upgraded Spotify (SPOT) to Buy from Ne…
Jennifer Garner’s Once Upon a Farm Rises Nearly 20% to Wrap Up Busy Week for IPOs
Jennifer Garner’s Sidney Bristow character from the TV show Alias and Elektra in Marvel movies may have faced formidable foes. Garner is a co-founder and investor in the organic baby food company Once Upon a Farm which began trading Friday…
This Mobile App Marketing Firm Is Holding Off an IPO for Now
Liftoff Mobile has postponed its initial public offering, citing market conditions after another day of sharp declines in stocks. “Given current market conditions, we have made a business decision to take additional time before listing,” t…
Eikon Therapeutics nets a $381M IPO amid burst of biotech offerings
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Eikon Therapeutics, a star-studded biotechnology startup that raised more than $1 billion in…
Catalyst Watch: Amazon earnings, IPO blitz, gold swings, and the jobs report
[bad day at wall street] franckreporter Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MONDAY - FEBRUARY 2…
Eikon Therapeutics targets $908 million valuation in US IPO
Jan 28 (Reuters) - Drug developer Eikon Therapeutics said on Wednesday it was targeting a valuation of up to $908.2 million in its U.S. initial public offering, as biotech listings make a comeback. The Millbrae, California-based compan…